The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy

Thrombosis Research

Volumn 115, Issue 4, 2005, Pages 293-299

  Maghzal, Ghassan J ^a   Brennan, Stephen O ^a   George, Peter M ^a  

^a Laboratories   (New Zealand)

Author keywords

Fibrates; Fibrinogen; Polymerisation; Pregnancy; Sialic acid

Indexed keywords

BEZAFIBRATE; FIBRINOGEN; GEMFIBROZIL; SIALIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CATALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MASS SPECTROMETER; POLYMERIZATION; PREGNANCY; PRIORITY JOURNAL; THROMBOSIS;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; N-ACETYLNEURAMINIC ACID; PREGNANCY; PROTEIN SUBUNITS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THROMBIN TIME;

EID: 12544256533     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.08.013     Document Type: Article

References (31)

1. J.W. Weisel, C.V. Stauffacher, E. Bullitt, and C. Cohen A model for fibrinogen: domains and sequence Science 230 1985 1388 1391
2. R.R. Townsend, E. Hilliker, Y.T. Li, R.A. Laine, W.R. Bell, and Y.C. Lee Carbohydrate structure of human fibrinogen. Use of 300-MHz 1H-NMR to characterize glycosidase-treated glycopeptides J. Biol. Chem. 257 1982 9704 9710
3. C.V. Dang, C.K. Shin, W.R. Bell, C. Nagaswami, and J.W. Weisel Fibrinogen sialic acid residues are low affinity calcium-binding sites that influence fibrin assembly J. Biol. Chem. 264 1989 15104 15108
4. J. Martinez, J. Palascak, and C. Peters Functional and metabolic properties of human asialofibrinogen J. Lab. Clin. Med. 89 1977 367 377
5. M. Okude, A. Yamanaka, Y. Morimoto, and S. Akihama Sialic acid in fibrinogen: effects of sialic acid on fibrinogen-fibrin conversion by thrombin and properties of asialofibrin clot Biol. Pharm. Bull. 16 1993 448 452
6. D.K. Galanakis, J. Martinez, C. Mcdewitt, and F. Miller Human fetal fibrinogen: Its characteristics of delayed fibrin formation, high sialic acid and AP peptide content are more marked in pre-term than term samples Ann. N. Y. Acad. Sci. 408 1983 640 643
7. H.R. Gralnick, H. Givelber, and E. Abrams Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule N. Engl. J. Med. 299 1978 221 226
8. J. Martinez, J.E. Palascak, and D. Kwasniak Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease J. Clin. Invest. 61 1978 535 538
9. T. Hayes Dysfibrinogenemia and thrombosis Arch. Pathol. Lab. Med. 126 2002 1387 1390
10. J.E. Palascak, and J. Martinez Dysfibrinogenemia associated with liver disease J. Clin. Invest. 60 1977 89 95
11. Y. Stirling, L. Woolf, W.R. North, M.J. Seghatchian, and T.W. Meade Haemostasis in normal pregnancy Thromb. Haemost. 52 1984 176 182
12. U. Kjellberg, N.E. Andersson, S. Rosen, L. Tengborn, and M. Hellgren APC resistance and other haemostatic variables during pregnancy and puerperium Thromb. Haemost. 81 1999 527 531
13. P. Comeglio, S. Fedi, A.A. Liotta, A.P. Cellai, E. Chiarantini, and D. Prisco Blood clotting activation during normal pregnancy Thromb. Res. 84 1996 199 202
14. G.N. Levine, J.F. Keaney Jr., and J.A. Vita Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms N. Engl. J. Med. 332 1995 512 521
15. M.P. de Maat Effects of diet, drugs and genes on plasma fibrinogen levels Ann. N. Y. Acad. Sci. 936 2001 509 521
16. L.O. Almer, and T. Kjellstrom The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia Atherosclerosis 61 1986 81 85
17. G. Niort, A. Bulgarelli, M. Cassader, and G. Pagano Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients Atherosclerosis 71 1988 113 119
18. M.P. de Maat, H.C. Knipscheer, J.J. Kastelein, and C. Kluft Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia Thromb. Haemost. 77 1997 75 79
19. A. Branchi, A. Rovellini, D. Sommariva, A.G. Gugliandolo, and A. Fasoli Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia Thromb. Haemost. 70 1993 241 243
20. H.C. Wilkes, T.W. Meade, S. Barzegar, A.J. Foley, L.O. Hughes, and K.A. Bauer Gemfibrozil reduces plasma prothrombin fragment F1+2 concentration, a marker of coagulability, in patients with coronary heart disease Thromb. Haemost. 67 1992 503 506
21. M. Kockx, M.P. de Maat, H.C. Knipscheer, J.J. Kastelein, C. Kluft, and H.M. Princen Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients Thromb. Haemost. 78 1997 1167 1172
22. A. Clauss Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens Acta Haematol. 17 1957 237 246
23. S.O. Brennan, B. Hammonds, and P.M. George Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (Aα20 Val→Asp) J. Clin. Invest. 96 1995 2854 2858
24. S.O. Brennan Electrospray ionisation analysis of human fibrinogen Thromb. Haemost. 78 1997 1055 1058
25. M.E. Carr Jr., and J. Hermans Size and density of fibrin fibers from turbidity Macromolecules 11 1978 46 50
26. T. Diaz-Maurino, C. Castro, and A. Albert Desialylation of fibrinogen with neuraminidase. Kinetic and clotting studies Thromb. Res. 27 1982 397 403
27. L. Warren The thiobarbituric acid assay of sialic acids J. Biol. Chem. 234 1959 1971 1975
28. F. Cerneca, G. Ricci, R. Simeone, M. Malisano, S. Alberico, and S. Guaschino Coagulation and fibrinolysis changes in normal pregnancy-increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis Eur. J. Obstet. Gynaecol. Reprod. Biol. 73 1997 31 36
29. P.N. Durrington, M.I. Mackness, D. Bhatnagar, K. Julier, H. Prais, and S. Arrol Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia Atherosclerosis 138 1998 217 225
30. A. Branchi, A. Rovellini, D. Sommariva, A.G. Gugliandolo, and A. Fasoli Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia Thromb. Haemost. 70 1993 241 243
31. M. Kockx, P.P. Gervois, P. Poulain, B. Derudas, J.M. Peters, and F.J. Gonzalez Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha Blood 93 1999 2991 2998